Lanfang Li

机构：Ministry of Education of the People's Republic of China, Guangxi University, State Grid Corporation of China (China), China-Japan Friendship Hospital, Tianjin Medical University Cancer Institute and Hospital, Guangxi University of Chinese Medicine, NARI Group (China), Shenzhen Second People's Hospital, Huazhong University of Science and Technology, University of South China · ORCID：0000-0003-3030-1739

发表论文 174 篇 · 总被引 1331 次 · h-index 21

代表论文

• Mitigation of renal tubular injury by SIRT6 may improve individual outcomes in diabetic kidney disease-potential mechanisms involving epigenetic repression of inflammatory responses (2025 · Journal of Advanced Research · 被引 5)
• Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults (2025 · Blood Advances · 被引 5)
• Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses (2025 · Leukemia · 被引 5)
• Comprehensive Analysis of Single‐Cell and Bulk Transcriptomics Identified Regulatory T‐Cell Features as Predictors of Prognosis in Diffuse Large B‐Cell Lymphoma (2025 · Hematological Oncology · 被引 4)
• Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2025 · Blood · 被引 3)
• Cell‐Type Specific Circuits in the Mammillary Body for Place and Object Recognition Memory (2025 · Advanced Science · 被引 3)